Categories Earnings, Health Care

Johnson & Johnson tumbles on rating downgrade, after opioid ruling

Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood remained downbeat in the wake of the court slapping a massive fine on the company in an opioid-related case.

Adding to the drugmaker’s woes, Moody’s on Wednesday lowered its outlook to negative from stable, while maintaining the Aaa rating. The rating agency believes that the ongoing opioid litigation might cause further damage to the company.

 US painkiller market is estimated to grow to $5.9 billion

According to Moody’s, in addition to the current lawsuit, Johnson & Johnson also faces social risks from cases related to its talc products, which will have an increasing impact on the company’s credit profile over the next one-and-half years. “The negative outlook reflects the potential for material litigation-related cash outflows that constrain J&J’s otherwise strong free cash flow or reduce the strength of its capital structure,” said a statement from the agency.

Also read: Teva’s Q2 results beat market expectations

Earlier this week, an Oklahoma court imposed a $572-million fine after finding Johnson & Johnson and its subsidiaries guilty of contributing to the health crisis facing the state due to the misuse of opioid medications. Soon after the landmark ruling, the company’s stock entered into a downward spiral and has lost about 4% since then.

A statement from the company said it is planning to appeal the order to the Oklahoma Supreme Court. The state is currently dealing with several hundreds of lawsuits filed by social groups and institutions, accusing the leading pharmaceutical companies of pushing opioid drugs into the market, breaching the safety norms.

Also see: Johnson & Johnson Q2 2019 Earnings Call Transcript

Purdue Pharma, the worst affected drugmaker, was earlier asked to pay $270 million in fine, while Teva Pharmaceuticals (TEVA) was awarded an $85-million fine. It is alleged that more than 4,000 persons died in the Oklahoma state in the last decade due to opioid-related health issues.

Also Read:  Illumina (ILMN) is uniquely placed to offer long-term returns. Here's why

Other than the relatively large penalty, what makes the case of Johnson & Johnson critical is the Judge calling it “a kingpin company” that acted irresponsibly, motivated by greed.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Palantir Technologies (PLTR) to start trading tomorrow through direct listing

The IPO market witnessed a boom in 2020, despite the pandemic weakening the macro environment. Many tech companies have witnessed a blockbuster listing this year and few more tech firms

Micron (MU) Q4 earnings, revenue top expectations

Micron Technology Inc. (NASDAQ: MU) reported strong earnings and revenue growth for the fourth quarter of 2020, benefitting from the pandemic-driven digital transformation spree. However, the company's stock dropped during

After a strong year thus far, Zynga (ZNGA) appears well-positioned for 2021 as well

Mobile game company Zynga Inc. (NASDAQ: ZNGA) has seen its stock gain 49% since the beginning of this year. The company registered strong results in the first half of 2020

2 thoughts on “Johnson & Johnson tumbles on rating downgrade, after opioid ruling

Comments are closed.

Top